Production of cow’s milk free from beta-casein A1 and application in early infant nutrition

Monday, Jan 21, 2019

Reference:

Duarte-Vázquez MA, Garciá-Ugalde C, Villegas-Gutiérrez LM, Garcia-Almendárez BE, Rosado JL. Production of cow’s milk free from beta-casein A1 and its application in the manufacturing of specialized foods for early infant nutrition. Foods. 2017;6:50.
Link to full publication: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532557/
 

Other article that you might be interested in:

Early feeding of low-protein formula and mental performance at 8 years of age

Background:

  • Beta-casein (BC) is the second most abundant protein in cow’s milk (27% of total protein) and has been found to play an important role in immune, cardiovascular, gastrointestinal and central nervous systems
  • BC has 13 genetic variants, resulting from single nucleotide polymorphisms (SNP) in the CSN2 gene, and the most common variants found in western dairy breeds are BC A1 and BC A2
  • BC A1 and BC A2 variants differ by a single amino acid (histidine vs. proline at amino acid position 67 respectively)
  • The presence of His67 in BC A1 facilitates the release of a seven-amino-acid peptide called beta-casomorphin 7 (BCM7) after digestion, while this is less likely in the case of BC A2 with Pro67
  • BCM7 displays potent opioid activity and is associated with adverse health effects such as slowed gastrointestinal motility in humans and clinical severity of autism spectrum disorders (ASD) in children

Methods:

  • Genotyping and selection of Jersey cows on the basis of the CSN2 A2 SNP, where animals with the CSN2 A2A2 genotype were selected and bred to produce milk containing BC A2 free from BC A1
  • The resultant BC A2 milk was added to formulation of an infant formula (BC A2 IF)
  • Concentrations of BCM7 release from human milk, BC A2 milk, BC A2 IF and commercially available IF (cow’s milk based with similar total protein content) were evaluated after simulated gastrointestinal digestion (SGID)

Results:

  • Relative abundance of BC A2 in BC A2 milk was 0.998 ± 0.008, with BC A1 level not detected
  • There were no significant differences in total BC concentration between the different IF tested (p = 0.062), but differences were observed in the amount of BCM7 released

 

  Quantity of BCM7 in SGID hydrolysates (ug/100mL) (mean ± SEM)
BC A2 IF 0.860 ± 0.014
Commercial IF 2 2.625 ± 0.042*
Commercial IF 3 1.693 ± 0.012*
Commercial IF 4 1.962 ± 0.067*
Human milk 0.697 ± 0.007#
BC A2 milk 0.742 ± 0.008#

*Quantity level is significantly higher than BC A2 IF, p < 0.05
#Quantity level is significantly lower than BC A2 IF, p < 0.05
 

Conclusion:

  • The selection of Jersey cows was able to produce milk comprised of BC A2 without BC A1, which may be used commercially for IF formulation
  • SGID revealed BC A2 IF released significantly lower amounts of BCM7 compared to normal cow’s milk based IF
  • This study provided insights to direct future investigations into the clinical application of BC A2 protein in infant health

Production of cow’s milk free from beta-casein A1 and application in early infant nutrition

Monday, Jan 21, 2019

Reference:

Duarte-Vázquez MA, Garciá-Ugalde C, Villegas-Gutiérrez LM, Garcia-Almendárez BE, Rosado JL. Production of cow’s milk free from beta-casein A1 and its application in the manufacturing of specialized foods for early infant nutrition. Foods. 2017;6:50.
Link to full publication: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532557/
 

Other article that you might be interested in:

Early feeding of low-protein formula and mental performance at 8 years of age

Background:

  • Beta-casein (BC) is the second most abundant protein in cow’s milk (27% of total protein) and has been found to play an important role in immune, cardiovascular, gastrointestinal and central nervous systems
  • BC has 13 genetic variants, resulting from single nucleotide polymorphisms (SNP) in the CSN2 gene, and the most common variants found in western dairy breeds are BC A1 and BC A2
  • BC A1 and BC A2 variants differ by a single amino acid (histidine vs. proline at amino acid position 67 respectively)
  • The presence of His67 in BC A1 facilitates the release of a seven-amino-acid peptide called beta-casomorphin 7 (BCM7) after digestion, while this is less likely in the case of BC A2 with Pro67
  • BCM7 displays potent opioid activity and is associated with adverse health effects such as slowed gastrointestinal motility in humans and clinical severity of autism spectrum disorders (ASD) in children

Methods:

  • Genotyping and selection of Jersey cows on the basis of the CSN2 A2 SNP, where animals with the CSN2 A2A2 genotype were selected and bred to produce milk containing BC A2 free from BC A1
  • The resultant BC A2 milk was added to formulation of an infant formula (BC A2 IF)
  • Concentrations of BCM7 release from human milk, BC A2 milk, BC A2 IF and commercially available IF (cow’s milk based with similar total protein content) were evaluated after simulated gastrointestinal digestion (SGID)

Results:

  • Relative abundance of BC A2 in BC A2 milk was 0.998 ± 0.008, with BC A1 level not detected
  • There were no significant differences in total BC concentration between the different IF tested (p = 0.062), but differences were observed in the amount of BCM7 released

 

  Quantity of BCM7 in SGID hydrolysates (ug/100mL) (mean ± SEM)
BC A2 IF 0.860 ± 0.014
Commercial IF 2 2.625 ± 0.042*
Commercial IF 3 1.693 ± 0.012*
Commercial IF 4 1.962 ± 0.067*
Human milk 0.697 ± 0.007#
BC A2 milk 0.742 ± 0.008#

*Quantity level is significantly higher than BC A2 IF, p < 0.05
#Quantity level is significantly lower than BC A2 IF, p < 0.05
 

Conclusion:

  • The selection of Jersey cows was able to produce milk comprised of BC A2 without BC A1, which may be used commercially for IF formulation
  • SGID revealed BC A2 IF released significantly lower amounts of BCM7 compared to normal cow’s milk based IF
  • This study provided insights to direct future investigations into the clinical application of BC A2 protein in infant health


WYE-EM-244-SEP-17

Latest Articles

Academic Activities

Scientific symposium – Critical connectivity: Assessing and supporting the development of brain and behaviour

Chairperson:

  • Dr Henry Au Yeung Cheuk-lun (Hong Kong)
Speakers:
  • Professor Weili Lin (USA)
  • Dr Daniel Chiu Cheung-shing (Hong Kong)
  • Dr Fanny Lam Wai-fan (Hong Kong)

The 28th International Congress of Pediatrics (IPA) (NEW!)

17-22 August 2016, Vancouver, Canada

Science Updates

Infants are exposed to human milk oligosaccharides (HMOs) already in utero (NEW!)

This is the first study to find that human milk oligosaccharides (HMOs) is present in amniotic fluid and that the fetus is exposed to HMOs in utero already.

Infant feeding tolerance on formula supplemented with sn-2 palmitate and oligofructose

This study explored the stool characteristics and feeding tolerances of infants fed formulas supplemented with sn-2 palmitate and oligofructose, both exclusively and when mixed-fed with human milk.

Resources

Picky Eating eBook

Practical tips to overcome picky eating behaviours by Kate Di Prima, an accredited practicing dietitian specializing in Paediatrics and a spokesperson for the Dietitians Association of Australia. 

Growth Charts

The WHO Child Growth Standards were developed using data collected in the WHO Multicentre Growth Reference Study (MGRS)1.